Hoth Therapeutics, Inc. (HOTH) — 10-Q Filings

10-Q Filings (6)

• Hoth Therapeutics' Losses Widen Amid Soaring R&D Costs — Nov 12, 2025 Risk: high
  Hoth Therapeutics, Inc. reported a net loss of $4,105,801 for the three months ended September 30, 2025, significantly wider than the $2,229,017 loss for the sa
• Hoth Therapeutics Files 10-Q, Remains Pre-Revenue Biotech — Aug 12, 2025 Risk: high
  Hoth Therapeutics, Inc. (HOTH) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-revenue biotechnology status. The company contin
• Hoth Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Nevada, is in the pharmaceutic
• Hoth Therapeutics Files Q3 2024 10-Q Report — Nov 12, 2024 Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending September 30, 2024. The company, incorporated in Nevada, is involved in th
• Hoth Therapeutics Files Q2 2024 10-Q Report — Aug 9, 2024 Risk: low
  Hoth Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Nevada, is involved in the phar
• Hoth Therapeutics, Inc. Files 10-Q for Period Ended March 31, 2024 — May 14, 2024 Risk: low
  Hoth Therapeutics, Inc. (HOTH) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Hoth Therapeutics, Inc. filed a 10-Q report for the quarterly perio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX